Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a definitive agreement for Novartis to acquire…
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders Biocytogen Pharmaceuticals a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, announced a strategic collaboration with…
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer Inc. and Valneva SE announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its…
NuScale Power and Ebara Elliott Energy Announce a Strategic Partnership to Showcase Use of Advanced Nuclear Technology to Power Petrochemical Plants NuScale Power Corporation the industry-leading provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology, and Ebara…
ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced…
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a…
PhaseWell Research Acquires Chase Medical Research to Expand Clinical Trial Capabilities in Connecticut PhaseWell Research a multisite clinical research company, today announced the strategic acquisition of Chase Medical Research (“CMR”). Under the leadership of founder, key opinion leader, and lead…
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment…
GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications GCE®, a global market leader for gas control equipment, has launched a new website designed to better serve customers across its GCE Specialty, GCE…
Flowserve Appoints Brian Savoy to Board of Directors Flowserve Corporation, a global leader in flow control products and services for infrastructure markets, has announced the appointment of Brian Savoy to its Board of Directors. His appointment became effective on March…